EUCTR2009-014387-20-GB进行中（未招募）1 期
An Open-Label Study to Evaluate the Single-Dose Pharmacokinetics, Safety, and Tolerability of Doripenem in Infants (Term and Preterm), Less Than 12 Weeks Chronological Age Protocol DORI-PED-1003; Phase 1
Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium0 个研究点目标入组 52 人开始时间: 2009年8月7日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 52
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Boy or girl <12 weeks CA
- •2.Subjects must be medically stable, without acute decline in physical condition in the investigator's judgment
- •3.A parent or the subject's legally acceptable representative must have signed an informed consent document indicating they understand the purpose of and procedures required for the study and are willing to allow the child to participate in the study as described in Section 11.2.3, Informed Consent, and as approved by institutional-specific guidelines
- •4.Documented, presumed to have, or are at risk for bacterial infection(s) and are undergoing treatment with i.v. antibiotics
- •5.Subject's weight (kg) must be within the 5th and the 95th percentile inclusive for his or her age
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Clinically significant abnormal values for hematology or clinical chemistry at screening as deemed appropriate by the investigator. If the results of the chemistry or hematology tests are outside normal reference ranges for a subject’s age, even if considered to be clinically significant, the subject can be included if, in the investigator's judgment, the abnormalities are consistent with the subject's underlying disease(s) or therapies. This determination must be recorded in the subject’s source documents and initialed by the investigator.
- •2.Clinically significant abnormal physical examination or vital signs at screening as deemed appropriate by the investigator. If the results of the physical examination or vital signs are outside normal reference ranges for a subject’s age, even if considered to be clinically significant, the subject can be included if, in the investigator's judgment, the abnormalities are consistent with the subject's underlying disease(s) or therapies. This determination must be recorded in the subject’s source documents and initialed by the investigator.
- •3.Subjects who, in the investigator's judgment, have compromised renal function
- •4.History of clinically significant allergies to medications, especially known hypersensitivity or intolerance to carbapenems, penicillins, or other B lactam antibiotics
- •5.Known allergy to heparin or history of heparin-induced thrombocytopenia, if an indwelling cannula (e.g., heparin lock) or central line is used
- •6.Subjects concomitantly treated with or having received imipenem/cilastin within 48 hours before study drug administration
- •7.Subjects concomitantly treated with probenecid or VPA
- •8.Subjects with hematocrit levels <30% within 48 hours before study drug administration
- •9.Subjects who are anticipated to need a blood transfusion during the open-label phase of the study
- •10.Subjects who are fluid restricted to the extent that would not allow for necessary volume of study drug administration
- •11.Received an experimental drug or used an experimental medical device within 1 month or within a period <10 times the drug’s half-life, whichever is longer, before the first dose of the study drug is scheduled
- •12.Preplanned surgery or procedures that would interfere with the conduct of the study
- •13.Family member of the employee of the investigator or study center, with direct involvement in the proposed study or other studies under the direction of that investigator or study center
研究者
相似试验
进行中（未招募）
1 期
A pharmacokinetic study to see the effect of Zevtera, a new infusion antibiotic, in babies younger than or equal 3 months.EUCTR2013-004614-18-LTBasilea Pharmaceutica International Ltd.45
进行中（未招募）
不适用
A Study to Evaluate the Pharmacokinetics and Safety of Doripenem in Children and Adolescents with Cystic FibrosisCystic fibrosisEUCTR2015-001225-16-Outside-EU/EEAJohnson & Johnson Pharmaceutical Research & Development L.L.C22
进行中（未招募）
1 期
A pharmacokinetic study to see the effect of Zevtera, a new infusion antibiotic, in babies younger than or equal 3 months.EUCTR2013-004614-18-LVBasilea Pharmaceutica International Ltd.45
进行中（未招募）
1 期
A pharmacokinetic study to see the effect of Zevtera, a new infusion antibiotic, in babies younger than or equal 3 months.EUCTR2013-004614-18-PLBasilea Pharmaceutica International Ltd.15
进行中（未招募）
不适用
A Study of Doripenem in Infants Less Than 12 Weeks of AgeHospitalized but medically stable infants (term and preterm), <12 weeks CA, who have documented, presumed to have, or are at risk for bacterial infection(s) and are undergoing treatment with i.v. antibiotics.MedDRA version: 14.0Level: LLTClassification code 10004044Term: Bacterial infection NOSSystem Organ Class: 10021881 - Infections and infestationsEUCTR2009-014387-20-Outside-EU/EEAJanssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium48